Medarex

From Wikipedia, the free encyclopedia

Medarex ( former NASDAQ symbol: MEDX ) is an American biotechnology company owned by Bristol Myers Squibb and based in Princeton, New Jersey.

Medarex is developing monoclonal antibodies to CTLA-4 and PD-1, which are proteins on the surface of T cells. T cells attack cancer cells, but CTLA-4 and PD-1 act as brakes on the T cell's anti-cancer activities. The monoclonal antibodies bind to those proteins, and release the T cell to attack cancer cells.[1][2]

In 2011, the U.S. Food and Drug Administration approved Ipilimumab, a monoclonal antibody to CTLA-4, for treatment of metastatic melanoma. The cost is $120,000 for a cost of treatment.[1]

The company has manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California.


References

  1. ↑ 1.0 1.1 Breakthrough of the Year: Cancer Immunotherapy, Science 20 December 2013, Vol. 342 no. 6165 pp. 1432-1433, DOI: 10.1126/science.342.6165.1432, Jennifer Couzin-Frankel
  2. ↑ ClinicalTrials.gov NCT00094653

External links

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.